Bill the medical benefit, and see what every fill actually earned.
XiFin Pharmacy Solutions is the former OmniSYS, and it carries one of the longest track records in pharmacy medical billing anywhere. If billing muscle at scale is what you need, they are a serious company and they belong on your shortlist. Billing is one of eight products here, running on the same connection as margin, audit, prior authorization and purchasing.
A quarter century of pharmacy medical billing, at national scale.
Genuine chain and health system scale
XiFin announced the OmniSYS acquisition as a provider "serving four of the top five national chains", and the pharmacy division has stated a reach of over 30,000 pharmacies across multiple releases. In 2026 the company states it is a business partner to more than half of pharmacies in the United States. Those are XiFin's own published figures, and they describe a company operating at national scale.
Medical billing as the core discipline
The pharmacy division describes itself in terms of medical billing, pharmacy workflow enabled solutions and patient engagement software. OmniSYS also built Strand-Rx, which it described as the industry's first pharmacy-specific electronic health record, and said it supported over 1.2 million pharmacist-provided clinical encounters in a year. Very few vendors in this market carry that much clinical billing history.
Real RCM lineage, from diagnostics
XiFin's heritage is revenue cycle management for laboratories and diagnostic providers, and its own description is of technology that facilitates connectivity and workflow automation across diagnostic, retail pharmacy and oncology markets. Denials work, appeals and payor response interpretation are native disciplines there.
Rate transparency as a first-class problem
XiFin introduced a Payor Rate Transparency Monitor in December 2023, comparing contracted rates published by UnitedHealthcare, Aetna and Cigna out of Transparency in Coverage data. That product serves diagnostic providers and radiology rather than pharmacy. Building it at all says something right about where a company thinks reimbursement leverage comes from.
Eight products, one connection, one contract.
A pharmacy that buys billing gets billing, and where billing is the gap that is a rational purchase. The fill that adjudicated below your acquisition cost this morning is a different problem. So is the audit letter asking for two hundred claims, and the prior authorization that has been open for nine days. Solve those one vendor at a time, or solve them in one system. Eight products run on a single connection here, so the claim, the cost, the encounter and the evidence are already joined before anyone asks a question that needs all four.
What each side publishes, side by side.
The XiFin column is drawn from press releases, an event page and their own sitemap. Where their materials do not state a capability, the cell says so.
| Capability | Attergo | XiFin Pharmacy Solutions |
|---|---|---|
| Pharmacy medical billing | Yes. Encounter to 837P to 835, scrubbed before submission, with denials returned as work items carrying the payer reason. | Yes, and it is the core of the offering. Named in the pharmacy division description as medical billing alongside workflow and patient engagement software. |
| Automated denial prioritization and appeal generation | No equivalent. Denials arrive as work items carrying the payer reason, with appeal evidence already bound to the claim. | Yes, and further than we go. A XiFin event page describes AI-driven error and denial prioritization, payor response interpretation, and an Appeals Agent producing an appeals package aligned with payor policy. |
| Per-fill margin against your acquisition cost | Yes. Every claim priced seconds after adjudication against your own wholesaler invoice, with the cost source labeled and unknown cost never shown as profit. | Not stated in the materials we could retrieve. |
| PBM audit evidence and response packages | Yes. Every event archived as it arrived, documents bound to their claim on the day, and a response package exported from a pasted claim list. | Not stated in the materials we could retrieve. |
| Electronic prior authorization | Yes, as one of the eight products, started by the rejection itself and tracked to renewal. | Not stated in the materials we could retrieve. |
| Purchasing, dead stock and DSCSA | Yes, with buying decisions informed by the claims data in the same system. | Not stated in the materials we could retrieve. |
| Published pricing | Yes. Flat, per store, on the pricing page, never a percentage of collections. | Not published. |
| Scale and installed base | PioneerRx in production today, named on the integrations page, with documented import for other systems. | Substantially larger. XiFin states more than half of United States pharmacies as partners and over 30,000 pharmacies reached. |
Every entry in the XiFin Pharmacy Solutions column is drawn from the pages listed at the foot of this page. Where their own materials do not state a capability, the cell says so rather than guessing.
Two honest recommendations.
Choose XiFin Pharmacy Solutions if
you are a large chain, a health system outpatient operation or a specialty pharmacy with an existing revenue cycle department, and what you need is outsourced billing muscle at volume. A partner who has processed medical claims for pharmacy at national scale for two decades, who already sits inside enterprise procurement, and whose denials and appeals practice is mature. If billing throughput is the constraint and the rest of your stack is settled, buy the specialist.
Choose Attergo if
billing is one of several things going wrong at once and you would rather not solve them one vendor at a time. You also need to know which fills lost money this morning, to answer a PBM audit without three weeks of archaeology, to keep prior authorizations from going stateless, and to buy inventory with the claims data in view. The joins between those four are where the answers live, and one platform on one connection is what makes them possible.
The capability that carries most of this weight on our side is Billing, and it is one of eight on a single connection.
Every claim above traces to their own words.
- XiFin press release, 18 January 2022: OmniSYS acquisition, top five chains, Strand-Rx and 1.2 million clinical encounters
- XiFin press release, 4 April 2022: "OmniSYS, a XiFin Company", and the 30,000 pharmacies figure
- XiFin press release, 6 June 2024: OmniSYS as "the pharmacy division of XiFin, Inc.", medical billing and CareALERTS
- XiFin press release, 18 December 2023: the Payor Rate Transparency Monitor, for diagnostic providers
- XiFin press release, 22 May 2026: "a business partner to more than half of pharmacies across the United States"
- XiFin event page: denial prioritization, Appeals Agent and payor response interpretation
What we could not verify
XiFin's pharmacy pages under xifin.com render their body content client-side, and every attempt to retrieve them returned only the page shell. We therefore assert nothing about their payer connectivity specifics, claim submission mechanics, patient statement products or reporting and analytics products. Rows marked as not stated mean we could not find the capability published, not that it is absent. If you are evaluating XiFin, ask them these questions directly and take their answer over our table.
See both columns run against your own claims.
Thirty minutes, one facility, a read-only connection and credentials you can revoke. We come back with what your own last month actually cost you.
Comparison based on publicly available information as of 2 August 2026. Tell us if something here is out of date and we will fix it. sales@attergo.com